ClinicalTrials.gg
CompletedNCT00408629Updated May 3, 2011Results posted

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of adalimumab and placebo in Ulcerative Colitis, sponsored by Abbott. Completed at 108 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-03.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
518
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.

Enrollment
4th of 18
518 · median 152
Started
2006
with 2 others
Phase 3
10 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
2 of 18
Abbott

Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 10 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing adalimumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).

Read the detailed description

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).

The duration of the study was up to 65 weeks, including a Screening Period of up to 3 weeks, a double-blind (DB) placebo-controlled treatment period of up to 52 weeks, and a 70 day follow-up phone call for participants who prematurely discontinued or who did not enroll in the extension study NCT# 00573794 (M10-223).

Adult participants with moderate to severe UC (Mayo score of 6 to 12 points with endoscopy subscore of 2 to 3 points), confirmed by colonoscopy with biopsy or flexible sigmoidoscopy with biopsy, were to be enrolled at approximately 120 sites worldwide. Planned enrollment was 500 participants.

Participants were to be stratified by prior exposure to infliximab and/or other anti-TNF agents, and randomized in a 1:1 ratio to receive ADA or placebo by subcutaneous injection. Participants assigned to the ADA treatment arm were to receive an induction dose of 160 mg at Week 0 and 80 mg at Week 2, and 40 mg every other week (eow) starting at Week 4. Participants assigned to the placebo treatment arm were to receive matching placebo during the same period of time. At or after Week 10, participants who met the criteria for inadequate response could be switched to open-label (OL) ADA 40 mg eow beginning at Week 12. Inadequate response was defined as:

  • Partial Mayo score greater than or equal to Baseline score on 2 consecutive visits at least 14 days apart (for participants with a partial Mayo score of 4 to 7 at Baseline).
  • Partial Mayo score greater than or equal to 7 on 2 consecutive visits at least 14 days apart (for participants with a partial Mayo score of 8 or 9 at Baseline).

Participants who demonstrated inadequate response at 2 consecutive visits at least 14 days apart while on OL administration ADA 40 mg eow were permitted to dose escalate to ADA 40 mg weekly (ew). Participants with persistent inadequate response while on ADA 40 mg ew may have been discontinued from the study at the Investigator's discretion. Upon completion of the study, participants had the option to enroll into the OL extension Study M10-223 in which they could receive ADA treatment.

Efficacy and safety measurements were performed throughout the study. A follow-up phone call was made 70 days after the last dose of study drug to obtain information on any ongoing or new adverse events (AEs) for all participants who terminated early or who did not enroll in the OL extension study.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
  • Adalimumab
  • TNF Antagonist
  • Mayo Score
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants >=18 years of age and in good health (Investigator discretion) with a recent stable medical history
  2. Diagnosis of UC for greater than 90 days prior to Baseline
  3. Diagnosis of active UC confirmed by colonoscopy with or flexible sigmoidoscopy with biopsy during the Screening Period, with exclusion of infection
  4. Active UC with a Mayo score of 6 to 12 points and endoscopy subscore of 2 to 3 points, despite concurrent treatment with at least 1 of the following (oral or or both as defined below):

    • Stable oral corticosteroid dose (prednisone >= 20 mg/day or equivalent) for at least 14 days prior to Baseline or maintenance, corticosteroid dose (prednisone \< 20 mg/day or equivalent) for at least 40 days prior to Baseline

    and/or

    • At least a 90 day course of azathioprine (AZA) or 6-mercaptopurine (6-MP) prior to Baseline, with a dose of AZA >= 1.5 mg/kg/day or 6-MP >= 1 mg/kg/day (rounded to the nearest available tablet formulation), or a dose that is the highest tolerated by the participant (e.g., due to leukopenia, elevated liver enzymes, nausea) during that time. Participant must be on a stable dose for at least 28 days prior to Baseline.

    Concurrent therapy was not required for participants who were previously treated with corticosteroids or immunosuppressants (AZA or 6-MP) during the past 5 years and in the judgment of the Investigator have failed to respond to, or could not tolerate, their treatment.

  5. Participants may have been included if they had previously used an anti-tumor necrosis factor (TNF) agent (except ADA) and discontinued its use due to a loss of response or intolerance to the agent.
  6. Had to be able to self-administer or had caregiver who could reliably administer subcutaneous (SC) injections.
  7. Had to be able and willing to give written and to comply with the requirements of the study protocol.
  8. Female had to be either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or of childbearing potential and practicing an approved method of throughout the study and for 150 days after the last dose of study drug. Examples of approved methods of birth control included the following:

    • Condoms, sponge, foams, jellies, diaphragm, or intrauterine device
    • Oral, parenteral, intravaginal contraceptives for 90 days prior to study drug administration
    • A vasectomized partner The results of the serum pregnancy test performed at the Screening Visit and urine pregnancy test performed at the Baseline Visit must have been negative.
  9. Judged to be in generally good health as determined by the Investigator

Exclusion criteria

Exclusion Criteria:

  1. History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC, or planned bowel surgery.
  2. Received previous treatment with ADA or previous participation in an ADA clinical study.
  3. Received cyclosporine, tacrolimus, or mycophenolate mofetil within 30 days of Baseline.
  4. Received intravenous (IV) within 14 days of Screening or during the Screening Period.
  5. Received therapeutic enema or suppository, other than required for endoscopy, within 14 days of the Screening endoscopy and during the remainder of the Screening Period.
  6. Current diagnosis of fulminant colitis and/or toxic megacolon.
  7. Disease limited to the rectum (ulcerative proctitis).
  8. Current diagnosis of indeterminate colitis.
  9. Current diagnosis and/or history of Crohns disease (CD).
  10. Currently receiving total parenteral nutrition.
  11. Used aminosalicylates for \< 90 days before Baseline or not on a stable dose for at least 28 days before Baseline or discontinued use within 28 days of Baseline.
  12. Positive Clostridium difficile stool assay.
  13. Previously used infliximab or any anti-TNF agent within 56 days of Baseline.
  14. Previously used infliximab or any anti-TNF agent without clinical response at any time ("primary non-responder") unless subject experienced a treatment-limiting reaction.
  15. Infections requiring treatment with IV antibiotics, antivirals, or antifungals within 30 days of Baseline or oral antibiotics, antivirals, or antifungals within 14 days of Baseline.
  16. History of other than a successfully treated non- cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix. If the Screening colonoscopy/flexible sigmoidoscopy showed evidence of dysplasia or a malignancy, subject was not to be enrolled in the study.
  17. History of listeria, histoplasmosis, chronic or active infection, (HIV), immunodeficiency syndrome, central nervous system demyelinating disease, or untreated tuberculosis (TB).
  18. Female subject who was pregnant or breast-feeding or considering becoming pregnant during the study (there should be at least 150 days between the last dose of study drug and either conception or initiation of breast-feeding in women of ).
  19. Poorly controlled medical condition(s), such as uncontrolled diabetes, unstable ischemic heart disease, moderate to severe congestive heart failure (CHF), recent cerebrovascular accident, and any other condition, which in the opinion of the investigator, put the subject at risk by participation in the protocol.
  20. Received any agent within 30 days or 5 half lives prior to Baseline (whichever was longer).
  21. History of drug or alcohol abuse during the past year.
  22. Known to the of ADA as stated in the label.
  23. Any prior exposure to Tysabri® (natalizumab), or Orencia® (abatacept) or any other biological therapy [other than Kineret® (anakinra) and anti-TNF agents].
  24. Currently taking both budesonide and prednisone (or equivalent) simultaneously.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
518 participants (actual)

Study arms

  • Experimental
    adalimumab group

    Biological: adalimumab

  • Experimental
    placebo group

    Biological: placebo

Interventions

  • Biologicaladalimumab

    Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.

    Also known as: ABT-D2E7, Humira

  • Biologicalplacebo

    Matching Placebo for prefilled syringe, 40 mg,

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore (SFS), Rectal Bleeding Subscore (RBS), Endoscopy Subscore, and Physician's Global Assessment Subscore (PGA), each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 8

  2. Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 52

Secondary outcomes

  1. Proportion of Participants Who Achieved Sustained Clinical Remission Per Mayo Score at Both Week 8 and Week 52

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 8, Week 52

  2. Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 8

    Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in rectal bleeding subscore (RBS) of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 8

  3. Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 52

    Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 52

  4. Proportion of Participants Who Achieved Sustained Clinical Response Per Mayo Score at Both Week 8 and Week 52

    Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 8, Week 52

  5. Proportion of Participants Who Achieved Mucosal Healing at Week 8

    Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).

    Time frame: Week 8

  6. Proportion of Participants Who Achieved Mucosal Healing at Week 52

    Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).

    Time frame: Week 52

  7. Proportion of Participants Who Achieved Sustained Mucosal Healing at Both Week 8 and Week 52

    Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).

    Time frame: Week 8, Week 52

  8. Proportion of Participants Who Discontinued Corticosteroid Use Before Week 52 and Achieved Clinical Remission Per Mayo Score at Week 52

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Baseline to Week 52

  9. Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8

    The PGA includes the 3 other subscores (SFS, RBS, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from 0-3 as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).

    Time frame: Week 8

  10. Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8

    SFS ranges from 0-3 as follows: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal. The participant served as his/her own control.

    Time frame: Week 8

  11. Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8

    RBS ranges from 0-3 as follows: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed

    Time frame: Week 8

  12. Proportion of Participants Who Discontinued Corticosteroid Use for At Least 90 Days and Achieved Clinical Remission Per Mayo Score at Week 52

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Baseline to Week 52

  13. Proportion of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission Per Mayo Score (Sustained) at Both Weeks 32 and 52

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 32, Week 52

  14. Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 52

    Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

    Time frame: Week 52

  15. Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 8

    Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

    Time frame: Week 8

07

Results

Posted Mar 31, 2011

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab 160/80/40Placebo
Started258260
Completed161135
Not completed97125
Withdrew: Adverse event1327
Withdrew: Withdrawal by subject84
Withdrew: Lost to follow-up11
Withdrew: Lack of efficacy6373
Withdrew: Protocol violation15
Withdrew: Miscellaneous1115

Outcome measures

PrimaryProportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8

Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore (SFS), Rectal Bleeding Subscore (RBS), Endoscopy Subscore, and Physician's Global Assessment Subscore (PGA), each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 816.59.3
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.019 (Testing for ranked co-primary endpoints occurred in hierarchical order to control for multiple testing. Week 8 remission rate was tested first. If a significant difference in group rates was found at alpha=0.05, Week 52 rate was tested at alpha=0.05.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
PrimaryProportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52

Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 5217.38.5
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.004 (Testing for ranked co-primary endpoints occurred in hierarchical order to control for multiple testing. Week 8 remission rate was tested first. If a significant difference in group rates was found at alpha=0.05, Week 52 rate was tested at alpha=0.05.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Achieved Sustained Clinical Remission Per Mayo Score at Both Week 8 and Week 52

Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 8, Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Sustained Clinical Remission Per Mayo Score at Both Week 8 and Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Sustained Clinical Remission Per Mayo Score at Both Week 8 and Week 528.54.1
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.047 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 8

Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in rectal bleeding subscore (RBS) of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 8
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 850.434.6
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 52

Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 5230.218.3
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.002 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Achieved Sustained Clinical Response Per Mayo Score at Both Week 8 and Week 52

Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 8, Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Sustained Clinical Response Per Mayo Score at Both Week 8 and Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Sustained Clinical Response Per Mayo Score at Both Week 8 and Week 5223.812.2
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Achieved Mucosal Healing at Week 8

Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Mucosal Healing at Week 8
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Mucosal Healing at Week 841.131.7
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.032 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure were needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Achieved Mucosal Healing at Week 52

Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Mucosal Healing at Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Mucosal Healing at Week 5225.015.4
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.009 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Achieved Sustained Mucosal Healing at Both Week 8 and Week 52

Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).

Time frame:
Week 8, Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Sustained Mucosal Healing at Both Week 8 and Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Achieved Sustained Mucosal Healing at Both Week 8 and Week 5218.510.6
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.013 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Discontinued Corticosteroid Use Before Week 52 and Achieved Clinical Remission Per Mayo Score at Week 52

Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Discontinued Corticosteroid Use Before Week 52 and Achieved Clinical Remission Per Mayo Score at Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Discontinued Corticosteroid Use Before Week 52 and Achieved Clinical Remission Per Mayo Score at Week 5213.35.7
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.035 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8

The PGA includes the 3 other subscores (SFS, RBS, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from 0-3 as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 846.037.4
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.058 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8

SFS ranges from 0-3 as follows: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal. The participant served as his/her own control.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 837.928.5
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.028 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8

RBS ranges from 0-3 as follows: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 870.258.1
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.006 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Discontinued Corticosteroid Use for At Least 90 Days and Achieved Clinical Remission Per Mayo Score at Week 52

Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Discontinued Corticosteroid Use for At Least 90 Days and Achieved Clinical Remission Per Mayo Score at Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Discontinued Corticosteroid Use for At Least 90 Days and Achieved Clinical Remission Per Mayo Score at Week 5213.35.7
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.035 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission Per Mayo Score (Sustained) at Both Weeks 32 and 52

Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 32, Week 52
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission Per Mayo Score (Sustained) at Both Weeks 32 and 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission Per Mayo Score (Sustained) at Both Weeks 32 and 5210.01.4
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.002 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Inflammatory Bowel Disease Questionnaire Responders at Week 52

Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 52
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 5226.216.3
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.007 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.
SecondaryProportion of Inflammatory Bowel Disease Questionnaire Responders at Week 8

Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 8
Percentage of ParticipantsAdalimumab 160/80/40Placebo
Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 858.145.5
Statistical analysis
  • Adalimumab 160/80/40 vs Placebo · Cochran-Mantel-Haenszel · p = 0.006 (Testing of ranked secondary measures was only started if significant group differences existed for both co-primary measures. Significant results for higher-ranked measure was needed to test next lower-ranked measure to control for multiple testing.)Stratification levels for Cochran-Mantel-Haenszel = prior anti-TNF versus anti-TNF-naive.

Adverse events

Collected over Double-Blind (DB) period: From 1st study drug dose in DB period to 70 days after last DB study drug dose or until switch to Open-Label. Any Adalimumab: From 1st adalimumab dose up 70 days after last adalimumab dose or until switch to extension study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab Group - Double-Blind Period—31/257 (12.1%)139/257 (54.1%)
Placebo Group - Double-Blind Period—32/260 (12.3%)142/260 (54.6%)
Any Adalimumab—61/398 (15.3%)204/398 (51.3%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventAdalimumab Group - Double-Blind PeriodPlacebo Group - Double-Blind PeriodAny Adalimumab
Colitis ulcerativeGastrointestinal disorders16/25718/26035/398
Pyoderma gangrenosumSkin and subcutaneous tissue disorders0/2574/2600/398
AnaemiaBlood and lymphatic system disorders2/2571/2603/398
Deep vein thrombosisVascular disorders2/2571/2602/398
Abdominal painGastrointestinal disorders1/2570/2602/398
Inguinal herniaGastrointestinal disorders0/2570/2602/398
AppendicitisInfections and infestations1/2570/2602/398
LeukopeniaBlood and lymphatic system disorders1/2570/2601/398
Abdominal pain lowerGastrointestinal disorders1/2570/2601/398
ColitisGastrointestinal disorders1/2570/2601/398
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAdalimumab Group - Double-Blind PeriodPlacebo Group - Double-Blind PeriodAny Adalimumab
Colitis ulcerativeGastrointestinal disorders42/25758/26071/398
NasopharyngitisInfections and infestations45/25727/26068/398
HeadacheNervous system disorders22/25737/26031/398
NauseaGastrointestinal disorders15/25722/26023/398
ArthralgiaMusculoskeletal and connective tissue disorders20/25716/26030/398
Abdominal painGastrointestinal disorders19/25716/26027/398
FatigueGeneral disorders16/25715/26025/398
Oropharyngeal painRespiratory, thoracic and mediastinal disorders15/2577/26023/398
PyrexiaGeneral disorders11/25714/26023/398
AnaemiaBlood and lymphatic system disorders8/25714/26021/398

Baseline characteristics

Age Continuous
Age Continuous(Years)Adalimumab 160/80/40PlaceboTotal
Mean39.6 ± 12.4741.3 ± 13.2240.4 ± 12.86
Age, Customized
Age, Customized(Participants)Adalimumab 160/80/40PlaceboTotal
< 40 years136118254
40 to 64 years105116221
>=65 years71219
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 160/80/40PlaceboTotal
Female10694200
Male142152294
Region of Enrollment
Region of Enrollment(Participants)Adalimumab 160/80/40PlaceboTotal
Portugal213
United States7882160
Spain4711
Austria044
Israel505
France181432
Czech Republic182543
Hungary131326
Canada181937
Poland141529
Belgium261844
Australia11920
Denmark235
Norway516
Germany192241
New Zealand448
Switzerland11920
08

Study locations

108 sites
  • Site Ref # / Investigator 5394
    Anaheim, California 92801, United States
  • Site Ref # / Investigator 3753
    Wheat Ridge, Colorado 80033, United States
  • Site Ref # / Investigator 3754
    Hamden, Connecticut 06518, United States
  • Site Ref # / Investigator 12903
    Gainesville, Florida 32607, United States
  • Site Ref # / Investigator 3747
    Hollywood, Florida 33021, United States
  • Site Ref # / Investigator 5106
    Jacksonville, Florida 32256, United States
  • Site Ref # / Investigator 11601
    Naples, Florida 34102, United States
  • Site Ref # / Investigator 6846
    Sarasota, Florida 34239, United States
  • Site Ref # / Investigator 3742
    Winter Park, Florida 32789, United States
  • Site Ref # / Investigator 3760
    Zephyrhills, Florida 33542, United States
  • Site Ref # / Investigator 3739
    Atlanta, Georgia 30342, United States
  • Site Ref # / Investigator 7658
    Macon, Georgia 31201, United States
  • Site Ref # / Investigator 5397
    Moline, Illinois 61265, United States
  • Site Ref # / Investigator 7453
    Topeka, Kansas 66606, United States
  • Site Ref # / Investigator 3759
    Annapolis, Maryland 21401, United States
  • Site Ref # / Investigator 3762
    Annapolis, Maryland 21401, United States
  • Site Ref # / Investigator 3738
    Lutherville, Maryland 21093, United States
  • Site Ref # / Investigator 7472
    Troy, Michigan 48098, United States
  • Site Ref # / Investigator 3744
    Rochester, Minnesota 55905, United States
  • Site Ref # / Investigator 6088
    St. Louis, Missouri 63128, United States
  • Site Ref # / Investigator 3756
    Great Neck, New York 11021, United States
  • Site Ref # / Investigator 3752
    Charlotte, North Carolina 28207, United States
  • Site Ref # / Investigator 3758
    Jacksonville, North Carolina 28546, United States
  • Site Ref # / Investigator 3745
    Cincinnati, Ohio 45219, United States
  • Site Ref # / Investigator 7709
    Oklahoma City, Oklahoma 73104, United States
  • Site Ref # / Investigator 3740
    Tulsa, Oklahoma 74104, United States
  • Site Ref # / Investigator 3765
    Sayre, Pennsylvania 18840, United States
  • Site Ref # / Investigator 3741
    Columbia, South Carolina 29204, United States
  • Site Ref # / Investigator 3737
    Germantown, Tennessee 38138, United States
  • Site Ref # / Investigator 6077
    Nashville, Tennessee 37203, United States
  • Site Ref # / Investigator 5107
    Nashville, Tennessee 37205, United States
  • Site Ref # / Investigator 3743
    Nashville, Tennessee 37212-1610, United States
  • Site Ref # / Investigator 5398
    Ogden, Utah 84405, United States
  • Site Ref # / Investigator 8064
    Spokane, Washington 99202, United States
  • Site Ref # / Investigator 3750
    Spokane, Washington 99204, United States
  • Site Ref # / Investigator 3761
    West Bend, Wisconsin 53095, United States
  • Site Ref # / Investigator 6853
    Buenos Aires, C1181ACH, Argentina
  • Site Ref # / Investigator 13722
    Garran, Australian Capital Territory 2605, Australia
  • Site Ref # / Investigator 16141
    Bankstown, New South Wales NSW 2200, Australia
  • Site Ref # / Investigator 13723
    Herston, Queensland 4029, Australia
  • Site Ref # / Investigator 10706
    Bedford Park, South Australia SA 5042, Australia
  • Site Ref # / Investigator 14882
    Box Hill, Victoria 3128, Australia
  • Site Ref # / Investigator 9002
    Malvern, Victoria 3144, Australia
  • Site Ref # / Investigator 10704
    Fremantle, Western Australia 6160, Australia
  • Site Ref # / Investigator 9802
    Vienna, 1090, Austria
  • Site Ref # / Investigator 5256
    Bonheiden, 2820, Belgium
  • Site Ref # / Investigator 5253
    Brussels, 1070, Belgium
  • Site Ref # / Investigator 6225
    Brussels, 1200, Belgium
  • Site Ref # / Investigator 6079
    Ghent, 9000, Belgium
  • Site Ref # / Investigator 6078
    Leuven, 3000, Belgium
  • Site Ref # / Investigator 10423
    Kelowna, British Columbia B1Y 1Z9, Canada
  • Site Ref # / Investigator 3766
    Victoria, British Columbia V8T 5G4, Canada
  • Site Ref # / Investigator 3769
    Hamilton, Ontario L8N 3Z5, Canada
  • Site Ref # / Investigator 13556
    Sudbury, Ontario P3E 2N8, Canada
  • Site Ref # / Investigator 3736
    Toronto, Ontario M5G 1X5, Canada
  • Site Ref # / Investigator 3771
    Montreal, Quebec H3A 1A1, Canada
  • Site Ref # / Investigator 3764
    Montreal, Quebec H3G 1A4, Canada
  • Site Ref # / Investigator 3768
    Montreal, Quebec H3T 1E2, Canada
  • Site Ref # / Investigator 3770
    Quebec City, Quebec G1S 4L8, Canada
  • Site Ref # / Investigator 7021
    Ceske Budejovice, 370 87, Czech Republic
  • Site Ref # / Investigator 6307
    Hradec Kravlove 12, 500 12, Czech Republic
  • Site Ref # / Investigator 6606
    Olomouc, 775 20, Czech Republic
  • Site Ref # / Investigator 7481
    Prague 4, 140 21, Czech Republic
  • Site Ref # / Investigator 7479
    Prague 5, 15006, Czech Republic
  • Site Ref # / Investigator 6483
    Hvidovre, DK-2650, Denmark
  • Site Ref # / Investigator 7477
    Odense C, 5000, Denmark
  • Site Ref # / Investigator 6231
    Clichy, 92110, France
  • Site Ref # / Investigator 7476
    Lille Cedex, 59037, France
  • Site Ref # / Investigator 7475
    Pessac Cedex, 33600, France
  • Site Ref # / Investigator 7474
    Toulouse, 31059, France
  • Site Ref # / Investigator 15321
    Hamburg, 20148, Germany
  • Site Ref # / Investigator 9069
    Hamburg, 22559, Germany
  • Site Ref # / Investigator 14642
    Magdeburg, 39120, Germany
  • Site Ref # / Investigator 9067
    Minden, 32423, Germany
  • Site Ref # / Investigator 14761
    Muenster, 48159, Germany
  • Site Ref # / Investigator 14661
    Munich, 80639, Germany
  • Site Ref # / Investigator 9801
    Munich, 81377, Germany
  • Site Ref # / Investigator 5247
    Regensburg, 93053, Germany
  • Site Ref # / Investigator 7485
    Budapest, H-1076, Hungary
  • Site Ref # / Investigator 5025
    Budapest, H-1135, Hungary
  • Site Ref # / Investigator 10625
    Debrecen, 4032, Hungary
  • Site Ref # / Investigator 14104
    Gyula, 5700, Hungary
  • Site Ref # / Investigator 4987
    Miskoic, H-3051, Hungary
  • Site Ref # / Investigator 5036
    Miskolc, H-3526, Hungary
  • Site Ref # / Investigator 12744
    Kfar Saba, 44281, Israel
  • Site Ref # / Investigator 10623
    Petah Tikva, 49100, Israel
  • Site Ref # / Investigator 15361
    Tel Aviv, 64239, Israel
  • Site Ref # / Investigator 13301
    Auckland, 0620, New Zealand
  • Site Ref # / Investigator 13181
    Auckland, 1148, New Zealand
  • Site Ref # / Investigator 13148
    Christchurch, 8011, New Zealand
  • Site Ref # / Investigator 13482
    Hamilton, New Zealand
  • Site Ref # / Investigator 9561
    Gjovik, 2819, Norway
  • Site Ref # / Investigator 5197
    Oslo, 0027, Norway
  • Site Ref # / Investigator 6297
    Oslo, 0514, Norway
  • Site Ref # / Investigator 5194
    Tromso, 9038, Norway
  • Site Ref # / Investigator 5193
    Trondheim, 7006, Norway
  • Site Ref # / Investigator 5242
    Lodz, 90-153, Poland
  • Site Ref # / Investigator 5266
    Warsaw, 02 781, Poland
  • Site Ref # / Investigator 5265
    Warsaw, 02-507, Poland
  • Site Ref # / Investigator 15263
    Wroclaw, 54-144, Poland

Showing the first 100 of 108 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6. PubMed 29380251 ↗
  • Wolf D, D'Haens G, Sandborn WJ, Colombel JF, Van Assche G, Robinson AM, Lazar A, Zhou Q, Petersson J, Thakkar RB. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep;40(5):486-97. doi: 10.1111/apt.12863. Epub 2014 Jul 15. PubMed 25041859 ↗
  • Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014 Jan;146(1):110-118.e3. doi: 10.1053/j.gastro.2013.09.032. Epub 2013 Sep 22. PubMed 24067881 ↗
  • Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013 Jan;37(2):204-13. doi: 10.1111/apt.12145. Epub 2012 Nov 23. PubMed 23173821 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2006
First posted
Dec 7, 2006
Start
Nov 2006
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Mar 31, 2011
Last update
May 3, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00408629
Lead sponsor
Abbott
First posted
Dec 7, 2006
Start date
Nov 2006
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Mar 31, 2011
Last update
May 3, 2011

Study contacts

Roopal B Thakkar, M.D.
study director · Abbott

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion